RECURRENT LUNG NON-SMALL CELL CARCINOMA

This phase 2 trial tests whether combining two drugs, SX-682 and pembrolizumab, can shrink tumors in people with advanced non-small cell lung cancer that has spread or come back. The study will enroll 30 adults whose tumors have a certain protein (PD-L1) and who have not had prio…

This study tests an experimental oral drug called S241656 (BDTX-4933) in people with advanced solid tumors that have certain genetic changes (KRAS, BRAF, or other RAS/MAPK mutations). The trial has two parts: first, finding a safe dose, then testing how well it works alone or wit…

This early-phase trial tests a new type of immunotherapy for people with a specific kind of advanced lung cancer (FRa-positive NSCLC). Researchers take a patient's own immune cells, engineer them to recognize and attack cancer cells, and deliver them directly into the chest cavit…

This phase II trial is testing the drug osimertinib in 46 people with advanced non-small cell lung cancer that has a specific genetic change (EGFR exon 20 insertion). The goal is to see if the drug can shrink tumors or slow the cancer's growth. Participants will take osimertinib …

This study tests whether combining three targeted drugs (capmatinib, osimertinib, and ramucirumab) works better than two drugs alone for people with advanced non-small cell lung cancer that has specific EGFR and MET gene changes. The drugs block signals that help cancer grow and …

This study is for people with stage IV or returning non-small cell lung cancer who have already had chemotherapy and immunotherapy. It compares the usual two-drug treatment (docetaxel and ramucirumab) to the same two drugs plus a third drug called cemiplimab. The goal is to see i…

This study tests whether adding ramucirumab to tepotinib works better than tepotinib alone for people with advanced non-small cell lung cancer that has a specific MET gene mutation. About 56 participants will be randomly assigned to one of two treatment groups. The goal is to see…

This early-phase trial is testing a personalized vaccine made from each patient's unique tumor mutations. The vaccine is given along with an immune booster (poly ICLC) to help the body's T cells attack the cancer. The study includes up to 25 adults with advanced melanoma, breast …

This early-phase trial is testing whether combining two drugs—vismodegib and atezolizumab—is safe and tolerable for people with advanced non-small cell lung cancer that has returned or spread. Vismodegib blocks certain enzymes that help cancer cells grow, while atezolizumab helps…

This early-stage trial tests a new drug (PBF-1129) combined with an immunotherapy (nivolumab) in 30 adults with advanced non-small cell lung cancer that has returned or spread. The main goal is to find the safest dose and understand side effects. Participants must have already tr…

This study collects tissue samples from people with various advanced or early-stage cancers to train a diagnostic platform called Elephas. The goal is to see how accurately it can predict whether a patient will respond to immunotherapy or chemoimmunotherapy. About 324 participant…

This study looks at how PET/CT scans change during chemoimmunotherapy and radiation for stage IV non-small cell lung cancer. Researchers want to see if these scans can help predict how well the cancer responds to treatment. About 80 participants will undergo standard treatment al…